Clinical, Imaging, and Lab Correlates of Severe COVID-19 Leukoencephalopathy

References

1. 1.↵
   1. Helms J,
   2. Kremer S,
   3. Merdji H, et al

   . Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020;382:2268–70 doi:10.1056/NEJMc2008597 pmid:32294339

   CrossRefPubMed
2. 2.↵
   1. Pleasure SJ,
   2. Green AJ,
   3. Josephson SA

   . The spectrum of neurologic disease in the severe acute respiratory syndrome coronavirus 2 pandemic infection: neurologists move to the frontlines. JAMA Neurol 2020;77:679 doi:10.1001/jamaneurol.2020.1065 pmid:32275291

   CrossRefPubMed
3. 3.↵
   1. Yuki K,
   2. Fujiogi M,
   3. Koutsogiannaki S

   . COVID-19 pathophysiology: a review. Clin Immunol 2020;215:108427 doi:10.1016/j.clim.2020.108427 pmid:32325252

   CrossRefPubMed
4. 4.↵
   1. Radmanesh A,
   2. Derman A,
   3. Lui YW, et al

   . COVID-19-associated diffuse leukoencephalopathy and microhemorrhages. Radiology 2020;297:E223–27 doi:10.1148/radiol.2020202040 pmid:32437314

   CrossRefPubMed
5. 5.↵
   1. Couzin-Frankel J

   . The mystery of the pandemic’s “happy hypoxia.” Science 2020;368:455–56 doi:10.1126/science.368.6490.455 pmid:32355007

   Abstract/FREE Full Text
6. 6.↵
   1. Balan S,
   2. Gupta K,
   3. Balasundaram P, et al

   . Reversible hypoxic brain injury: the penumbra conundrum of Grinker. BMJ Case Rep 2019;12:e228670 doi:10.1136/bcr-2018-228670 pmid:31015246

   CrossRefPubMed
7. 7.↵
   1. Beeskow AB,
   2. Oberstadt M,
   3. Saur D, et al

   . Delayed post-hypoxic leukoencephalopathy (DPHL): an uncommon variant of hypoxic brain damage in adults. Front Neurol 2018;9:708 doi:10.3389/fneur.2018.00708 pmid:30210433

   CrossRefPubMed
8. 8.↵
   1. Breit H,
   2. Jhaveri M,
   3. John S

   . Concomitant delayed posthypoxic leukoencephalopathy and critical illness microbleeds. Neurol Clin Pract 2018;8:e31–33 doi:10.1212/CPJ.0000000000000513 pmid:30564507

   Abstract/FREE Full Text
9. 9.↵
   1. Zamora CA,
   2. Nauen D,
   3. Hynecek R, et al

   . Delayed posthypoxic leukoencephalopathy: a case series and review of the literature. Brain Behav 2015;5:e00364 doi:10.1002/brb3.364 pmid:26357591

   CrossRefPubMed
10. 10.↵
    1. Garofalo AM,
    2. Lorente-Ros M,
    3. Goncalvez G, et al

    . Histopathological changes of organ dysfunction in sepsis. Intensive Care Med Exp 2019;7:45 doi:10.1186/s40635-019-0236-3 pmid:31346833

    CrossRefPubMed
11. 11.↵
    1. Polito A,
    2. Eischwald F,
    3. Maho AL, et al

    . Pattern of brain injury in the acute setting of human septic shock. Crit Care 2013;17:R204 doi:10.1186/cc12899 pmid:24047502

    CrossRefPubMed
12. 12.↵
    1. Sharshar T,
    2. Carlier R,
    3. Bernard F, et al

    . Brain lesions in septic shock: a magnetic resonance imaging study. Intensive Care Med 2007;33:798–806 doi:10.1007/s00134-007-0598-y pmid:17377766

    CrossRefPubMed
13. 13.↵
    1. Shindo A,
    2. Suzuki K,
    3. Iwashita Y, et al

    . Sepsis-associated encephalopathy with multiple microbleeds in cerebral white matter. Am J Med 2018;131:e297–98 doi:10.1016/j.amjmed.2018.02.012 pmid:29530728

    CrossRefPubMed
14. 14.↵
    1. Mehta P,
    2. McAuley DF,
    3. Brown M, et al

    ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033–34 doi:10.1016/S0140-6736(20)30628-0 pmid:32192578

    CrossRefPubMed
15. 15.↵
    1. Moore BJ,
    2. June CH

    . Cytokine release syndrome in severe COVID-19. Science 2020;368:473–74 doi:10.1126/science.abb8925 pmid:32303591

    Abstract/FREE Full Text
16. 16.↵
    1. Solomon IH,
    2. Normandin E,
    3. Bhattacharyya S, et al

    . Neuropathological features of Covid-19. N Engl J Med 2020;383:989–92 doi:10.1056/NEJMc2019373 pmid:32530583

    CrossRefPubMed
17. 17.↵
    1. Kandemirli SG,
    2. Dogan L,
    3. Sarikaya ZT, et al

    . Brain MRI findings in patients in the intensive care unit with COVID-19 infection. Radiology 2020;297:E232–35 doi:10.1148/radiol.2020201697 pmid:32384020

    CrossRefPubMed
18. 18.↵
    1. Sachs JR,
    2. Gibbs KW,
    3. Swor DE, et al

    . COVID-19-associated leukoencephalopathy. Radiology 2020;296:E184–85 doi:10.1148/radiol.2020201753 pmid:32407258

    CrossRefPubMed
19. 19.↵
    1. Lang M,
    2. Buch K,
    3. Li MD, et al

    . Leukoencephalopathy associated with severe COVID-19 infection: sequela of hypoxemia? AJNR Am J Neuroradiol 2020;41:1641–45 doi:10.3174/ajnr.A6671 pmid:32586959

    Abstract/FREE Full Text
20. 20.↵
    1. Dearborn JL,
    2. Schneider AL,
    3. Sharrett AR, et al

    . Obesity, insulin resistance, and incident small vessel disease on magnetic resonance imaging: Atherosclerosis Risk in Communities Study. Stroke 2015;46:3131–36 doi:10.1161/STROKEAHA.115.010060 pmid:26451022

    Abstract/FREE Full Text
21. 21.↵
    1. Hakim AM

    . Small vessel disease. Front Neurol 2019;10:1020 doi:10.3389/fneur.2019.01020 pmid:31616367

    CrossRefPubMed
22. 22.↵
    1. Ter Telgte A,
    2. Wiegertjes K,
    3. Gesierich B, et al

    . Contribution of acute infarcts to cerebral small vessel disease progression. Ann Neurol 2019;86:582–92 doi:10.1002/ana.25556 pmid:31340067

    CrossRefPubMed
23. 23.↵
    1. Varga Z,
    2. Flammer AJ,
    3. Steiger P, et al

    . Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417–18 doi:10.1016/S0140-6736(20)30937-5 pmid:32325026

    CrossRefPubMed
24. 24.↵
    1. Lampe L,
    2. Zhang R,
    3. Beyer F, et al

    . Visceral obesity relates to deep white matter hyperintensities via inflammation. Ann Neurol 2019;85:194–203 doi:10.1002/ana.25396 pmid:30556596

    CrossRefPubMed
25. 25.↵
    1. Kataoka H,
    2. Izumi T,
    3. Kinoshita S, et al

    . Infarction limited to both middle cerebellar peduncles. J Neuroimaging 2011;21:e171–72 doi:10.1111/j.1552-6569.2010.00503.x pmid:20572906

    CrossRefPubMed
26. 26.↵
    1. Hayden SJ,
    2. Albert TJ,
    3. Watkins TR, et al

    . Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med 2012;185:1049–57 doi:10.1164/rccm.201110-1915CI pmid:22281832

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Houston DS

    . Hepcidin and the anemia of critical illness. Crit Care Med 2018;46:1030–31 doi:10.1097/CCM.0000000000003100 pmid:29762411

    CrossRefPubMed
28. 28.↵
    1. Nemeth E,
    2. Rivera S,
    3. Gabayan V, et al

    . IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271–76 doi:10.1172/JCI200420945 pmid:15124018

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Lippi G,
    2. South AM,
    3. Henry BM

    . Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). Ann Clin Biochem 2020;57:262–65 doi:10.1177/0004563220922255 pmid:32266828

    CrossRefPubMed
30. 30.↵
    1. Puelles VG,
    2. Lutgehetmann M,
    3. Lindenmeyer MT, et al

    . Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med 2020;383:590–92 doi:10.1056/NEJMc2011400 pmid:32402155

    CrossRefPubMed
31. 31.↵
    1. Meyer MA

    . Delayed post-hypoxic leukoencephalopathy: case report with a review of disease pathophysiology. Neurol Int 2013;5:e13 doi:10.4081/ni.2013.e13 pmid:24147210

    CrossRefPubMed
32. 32.↵
    1. de Oliveira AM,
    2. Paulino MV,
    3. Vieira AP, et al

    . Imaging patterns of toxic and metabolic brain disorders. Radiographics 2019;39:1672–95 doi:10.1148/rg.2019190016 pmid:31589567

    CrossRefPubMed
33. 33.↵
    1. Sener RN

    . Diffusion magnetic resonance imaging patterns in metabolic and toxic brain disorders. Acta Radiol 2004;45:561–70 doi:10.1080/02841850410006128 pmid:15515520

    CrossRefPubMed
34. 34.↵
    1. Gaitan-Penas H,
    2. Apaja PM,
    3. Arnedo T, et al

    . Leukoencephalopathy-causing CLCN2 mutations are associated with impaired Cl(-) channel function and trafficking. J Physiol 2017;595:6993–7008 doi:10.1113/JP275087 pmid:28905383

    CrossRefPubMed
35. 35.↵
    1. Guo Z,
    2. Lu T,
    3. Peng L, et al

    . CLCN2-related leukoencephalopathy: a case report and review of the literature. BMC Neurol 2019;19:156 doi:10.1186/s12883-019-1390-7 pmid:31291907

    CrossRefPubMed
36. 36.↵
    1. Rushworth CA,
    2. Guy JL,
    3. Turner AJ

    . Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. FEBS J 2008;275:6033–42 doi:10.1111/j.1742-4658.2008.06733.x pmid:19021774

    CrossRefPubMed
37. 37.↵
    1. Li RS,
    2. Wang Y,
    3. Chen HS, et al

    . TMEM16A contributes to angiotensin II-induced cerebral vasoconstriction via the RhoA/ROCK signaling pathway. Mol Med Rep 2016;13:3691–99 doi:10.3892/mmr.2016.4979 pmid:26955761

    CrossRefPubMed
38. 38.↵
    1. Nelson MT,
    2. Conway MA,
    3. Knot HJ, et al

    . Chloride channel blockers inhibit myogenic tone in rat cerebral arteries. J Physiol 1997;502:259–64 doi:10.1111/j.1469-7793.1997.259bk.x pmid:9263908

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Premji S,
    2. Kang L,
    3. Rojiani MV, et al

    . Multifocal necrotizing leukoencephalopathy: expanding the clinicopathologic spectrum. J Neuropathol Exp Neurol 2019;78:340–47 doi:10.1093/jnen/nlz003 pmid:30753632

    CrossRefPubMed
40. 40.↵
    1. Poyiadji N,
    2. Shahin G,
    3. Noujaim D, et al

    . COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology 2020;296:E119–20 doi:10.1148/radiol.2020201187 pmid:32228363

    CrossRefPubMed
41. 41.↵
    1. Paniz-Mondolfi A,
    2. Bryce C,
    3. Grimes Z, et al

    . Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020;92:699–702 doi:10.1002/jmv.25915 pmid:32314810

    CrossRefPubMed